Exploring the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

Saturday, March 14, 2020
6:30 PM – 8:30 PM
Philadelphia Marriott Downtown
Level 5, Grand Ballroom Salon B
1201 Market Street
Philadelphia, PA 19107

 

AGENDA

6:30 PM – 7:00 PM       Registration/Dinner Served

7:00 PM – 8:15 PM       Practitioner’s Edge SM  Scientific Session

8:15 PM – 8:30 PM       Question & Answer Session/Closing Remarks

 

PRACTITIONER’S EDGESM PANEL

Faculty Chair

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family Asthma Institute
National Jewish Health
Denver, Colorado

Faculty

Bradley E. Chipps, MD
Medical Director
Capital Allergy and Respiratory Disease Center
Sacramento, California

Monica Kraft, MD
Robert & Irene Flinn Endowed Professor of Medicine
Chair, Department of Medicine
University of Arizona
Tucson, Arizona

PROGRAM OVERVIEW

Until recently, treatment options for severe asthma with an eosinophilic phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES) were limited mostly to immunosuppression with oral corticosteroids (OCS) or other highly toxic systemic agents. An expanding understanding of the pathophysiology of these diseases has led to the identification of actionable therapeutic targets and more selective and better tolerated treatments for eosinophil reduction. This activity will employ an interactive patient simulation to address these issues, review strategies for improving recognition of the phenotypes of severe eosinophilic diseases affecting the lungs, and to help the clinician better navigate available treatments. The program has been designed to provide clinicians with knowledge and tools to ultimately improve symptoms, lighten the disease burden, and reduce exacerbations and OCS reliance for patients with severe asthma and associated eosinophil-mediated conditions.

PROGRAM FORMAT

Led by expert faculty, this interactive educational program will be conducted in the Practitioner’s EdgeSM format and will employ interactive 3D models and a patient case simulation to illustrate and reinforce key program objectives.

Audience members will interact with the 3D models and participate in simulation and interactive questions via provided iPads. This participation and the outcomes of the overall simulation will be the catalyst for faculty discussion and best-practice reinforcement. The overall goal of the program is to provide information that is highly relevant to current practice and actionable guidance to implement best-practice strategies.

TARGET AUDIENCE

This educational initiative is intended for allergists and other advanced-care practitioners who manage patients with asthma and other eosinophilic-associated diseases.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA)
  • Explain why rarer orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma
  • Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on oral corticosteroids

REGISTRATION

There is no registration fee for attending this symposium; however, seating is limited. To register, click the registration buttons on this page or call Integrity Continuing Education, Inc. at 1-855-835-4004.  Preregistration does not guarantee seating. We recommend arriving at the meeting location early.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

A detailed disclosure for all persons in control of content, including faculty presenters, will be provided at the live event.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

This program is not sponsored or programmed by the AAAAI.

 

Provided by Integrity Continuing Education, Inc.

This educational activity is supported by an educational grant from GlaxoSmithKline.

 

Agenda

6:30 PM – 7:00 PM       Registration/Dinner Served

7:00 PM – 8:15 PM       Practitioner’s Edge SM  Scientific Session

8:15 PM – 8:30 PM       Question & Answer Session/Closing Remarks